A microbiome researcher thinks Ozempic lifts mood by getting your gut bacteria to make cannabis-like compounds
The theory: GLP-1 drugs feed a gut bacterium that produces endocannabinoids, calming the brain's stress centers — and in mice, the antidepressant effect vanished when the microbes were removed. The thread is the live human trial the mouse study isn't, and it complicates the tidy story.
A microbiome writer lays out a mechanism for why GLP-1 drugs lift mood: they grow a gut bacterium that makes cannabis-like endocannabinoids. In mice, removing the microbes erased the effect; a fecal transplant restored it.
Then the humans answered. One reports the opposite — anhedonia, a known side effect. Another lost insurance and now pays $450 a month, the returning weight 'making me more depressed.' Mice, as one reply noted, are not people.
The mechanism the article proposes
Writing in Psychology Today, microbiome author Scott C. Anderson offers a specific route from a weight-loss drug to a better mood, and it runs through the gut, not the brain directly. GLP-1 drugs, he writes, promote the growth of Lactobacillus delbrueckii, a bacterium that produces endocannabinoids — compounds that damp the stress response in the amygdala and hypothalamus, much as cannabis does. The supporting evidence is mouse-shaped but clean: people with depression have lower natural GLP-1 levels; in mice, GLP-1 drugs reversed depression-like behavior; that effect disappeared in germ-free mice, implicating the microbes directly; and transferring gut bacteria from treated mice to depressed ones improved their mood. Anderson's own caveat is the one the thread seized on: "mice are not humans, so keep that in mind."
The thread is the human cohort
Where the article has mice, the thread has people on the drugs right now, and they don't all confirm the mood story. The flat contradiction:
"Hasn't done jack shit for my depression. Also worth mentioning GLP-1's are known to cause anhedonia. So there's that." — a commenter reporting the opposite effect
A biologist-engineer added the durability problem the mechanism doesn't address:
"Studies show almost all subjects regained the weight and reversed gains within 2 years. This means underlying issues (e.g., food addiction) aren't being addressed. Short of changing habits, the only maintenance solution is lifelong drug use and that doesn't sit well with me." — a biologist and software engineer
The variable the biology ignores: the bill
The reply that grounds the whole debate isn't about neuroscience at all. It's about who can keep taking the drug:
"My insurance stopped covering, now I'm looking at $450 for Zepbound / month. Just the weight coming back is making me more depressed..." — a commenter on losing coverage
That's the reversal the gut-brain story can't reach. Even if Anderson is right that the drug lifts mood through endocannabinoids in the gut, the mechanism is gated by a pharmacy price, and a regimen that has to run for life to hold its gains becomes a depression risk the moment the coverage stops. The cleanest skeptical note in the thread — "mice are not people" — applies twice over: not just to the biology, but to the assumption that anyone who benefits will get to keep doing so.
Get breakdowns like this every day
The top Hacker News stories, unpacked — by email, Telegram, or RSS.
'Arrested for going 5 seconds over' went viral. The bodycam shows a longer story — and a worse one underneath
A farmer was handcuffed at a Claremore, Oklahoma council meeting about a data center. The viral framing — five seconds over a time limit — gets corrected in the thread by people who watched the footage. The grievance the headline buried is the real story.